Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription 15.09.2025 2 Am J Hematol 2 Blood 1 BMC Cancer 2 Eur J Haematol 1 Exp Hematol 1 Int J Hematol 1 J Pediatr Hematol Oncol 2 Leuk Lymphoma 1 Leuk Res 2 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. ORVAIN C, Bouvier A, Bidet A, Dumas PY, et al
   Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO Study.
   Am J Hematol. 2025 Sep 12. doi: 10.1002/ajh.70076.
   PubMed        
   
   
2. RU Y, Chen J, Ferhat AT, Labussiere-Wallet H, et al
   Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Commit
   Am J Hematol. 2025 Sep 10. doi: 10.1002/ajh.70069.
   PubMed         Abstract available
   
   

   
   Blood

3. PELZL R, Benintende G, Gsottberger F, Scholz JK, et al
   Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
   Blood. 2025 May 13:blood.2024027877. doi: 10.1182/blood.2024027877.
   PubMed         Abstract available
   
   
4. SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
   Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
   Blood. 2025;146:1276-1285.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. KAMEL AM, Almuslimani AM, Kandil EZ, Hanafy M, et al
   PD1/PDL1 and TIM3/Gal9 expression in acute lymphoblastic leukemia: Gal-9 expression on leukemia stem cells as an independent prognostic parameter.
   BMC Cancer. 2025;25:1421.
   PubMed         Abstract available
   
   

   
   Eur J Haematol

6. TOKUDA C, Iwasaki M, Kanda J, Kondo T, et al
   Significance of Pre- and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core-Binding Factor Acute Myeloid Leukemia.
   Eur J Haematol. 2025 Sep 9. doi: 10.1111/ejh.70024.
   PubMed         Abstract available
   
   
7. HANSEN MH, Gulmir R, Cedile O, Dahlmann SK, et al
   Performance of Rapid Clonotyping of Chronic Lymphocytic Leukemia Using Flongle Flow-Cell Nanopore Sequencing of IGH Rearrangements.
   Eur J Haematol. 2025 Sep 8. doi: 10.1111/ejh.70030.
   PubMed         Abstract available
   
   

   
   Exp Hematol

8. ERNST P, Kyei P, Yokoyama A
   KMT2A-rearranged leukemia: from mechanism to drug development.
   Exp Hematol. 2025 Sep 6:105247. doi: 10.1016/j.exphem.2025.105247.
   PubMed         Abstract available
   
   

   
   Int J Hematol

9. HAN W, Wang S, Zhang M, Fu S, et al
   Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia.
   Int J Hematol. 2025 Sep 10. doi: 10.1007/s12185-025-04064.
   PubMed         Abstract available
   
   

   
   J Pediatr Hematol Oncol

10. VASOVIC DD, Rasic DM, Pantelic J, Dacic-Krnjaja B, et al
    Isolated Anterior Segment Relapse in a Child With B-Cell Precursor Acute Lymphoblastic Leukemia: A Rare Case Report.
    J Pediatr Hematol Oncol. 2025 Sep 3. doi: 10.1097/MPH.0000000000003117.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

11. WANG Y, Xiao X, Zheng H, Bai J, et al
    The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Lymphoma. 2025 Sep 9:1-16. doi: 10.1080/10428194.2025.2549519.
    PubMed         Abstract available
    
    
12. PARISI X, Ghosh A, Tang G, Jorgensen JL, et al
    Lineage switch of B-lymphoblastic leukemia with KMT2A::AFF1 fusion into acute myelomonocytic leukemia under blinatumomab therapy.
    Leuk Lymphoma. 2025 Sep 8:1-4. doi: 10.1080/10428194.2025.2549515.
    PubMed        
    
    

    
    Leuk Res

13. ATALLAH EL, Sadek I, Wei D, Latremouille-Viau D, et al
    Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia.
    Leuk Res. 2025 Sep 5:108089. doi: 10.1016/j.leukres.2025.108089.
    PubMed         Abstract available
    
    

    
    Leukemia

14. MIRANDA-GALVIS M, Tjioe KC, Sharara M, Maloney M, et al
    Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia.
    Leukemia. 2025 Sep 11. doi: 10.1038/s41375-025-02763.
    PubMed         Abstract available
    
    
15. KANARI M, Jimenez Garcia I, Steffen FD, Krattiger LA, et al
    A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.
    Leukemia. 2025 Sep 10. doi: 10.1038/s41375-025-02739.
    PubMed         Abstract available
    
    

    
    PLoS One

16. YOON H, Park S, Kwon YR, Kim YJ, et al
    Potential role of miR-29b from mesenchymal stromal cell-derived extracellular vesicles in leukemic cell progression.
    PLoS One. 2025;20:e0328922.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.